ライフサイエンスコーパス: pharmacogenomics

1 ic basis of disease and drug response (i.e., pharmacogenomics).

2 functional approaches and model systems, and pharmacogenomics.

3 l applications in both genetic screening and pharmacogenomics.

4 genetic profiling studies), and host-related pharmacogenomics.

5 ll molecules and have clear implications for pharmacogenomics.

6 ic gene variants for medical diagnostics and pharmacogenomics.

7 genetic information, an application known as pharmacogenomics.

8 odules, with direct implications to clinical pharmacogenomics.

9 ing the realization of the full potential of pharmacogenomics.

10 impact and evolving evidence for clopidogrel pharmacogenomics.

11 at remain for the clinical implementation of pharmacogenomics.

12 o be important in disease susceptibility and pharmacogenomics.

13 atabase with direct implications in clinical pharmacogenomics.

14 interventions and assessing cancer risk and pharmacogenomics.

15 Pharmacogenomics addresses this issue by seeking to iden

16 an application of functional neuroimaging in pharmacogenomics and extend basic evidence of an inverte

17 A review of pharmacogenomics and how it affects the response to anal

18 developments in the field of cardiovascular pharmacogenomics and personalized medicine.

19 In the future, pharmacogenomics and point-of-care testing will likely p

20 Data from the Pharmacogenomics and Risk of Cardiovascular Disease (PAR

21 We discuss the implications for pharmacogenomics and the uncharted complexity in genotyp

22 is review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especi

23 level, the relationship between transporter pharmacogenomics and therapeutics in the age of individu

24 sed test to a sequencing study in anticancer pharmacogenomics and uncovered mechanistic insights into

25 fficiency may have important consequences in pharmacogenomics and variable drug toxicity observed in

26 ociation between genetics and drug response (pharmacogenomics) and the association of sequence variat

27 tion based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care.

28 with experimental medications in humans; the pharmacogenomics applied to these medications and disord

29 Systems pharmacology and pharmacogenomics are emerging to exploit the available d

30 Genomics and pharmacogenomics are signalling the start of a new era f

31 Pharmacogenomics attempts to elucidate the inherited bas

32 ic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of thera

33 ts leading mostly to monogenic disorders and pharmacogenomics biomarkers.

34 ut microenvironment, gut-brain interactions, pharmacogenomics, biopsychosocial, gender and cross cult

35 We cover the practical applications of pharmacogenomics both in the pharmaceutical industry and

36 In drug discovery, pharmacogenomics can be used to aid lead identification,

37 namic properties of pharmacological systems, pharmacogenomics can now provide an objective measure of

38 as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse rea

39 e publicly available International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset.

40 URPOSE To explore whether population-related pharmacogenomics contribute to differences in patient ou

41 a (CCLE) study as the benchmark dataset, all pharmacogenomics data exhibited their roles in inferring

42 based on integration of the heterogeneously pharmacogenomics data from both cell and drug sides.

43 Computational analysis of cancer pharmacogenomics data has resulted in biomarkers predict

44 By analyzing existing pharmacogenomics data, we propose the potential design o

45 We demonstrate how to integrate pharmacogenomics databases through integration of the bi

46 ried disease-specific mutation databases and pharmacogenomics databases to identify genes and mutatio

47 Samples collected in pharmacogenomics databases typically belong to various c

48 mation is currently distributed over several pharmacogenomics databases.

49 ients is very challenging; thus, most cancer pharmacogenomics discovery is conducted in preclinical s

50 to review the state of research on metformin pharmacogenomics, discuss the scientific and clinical hu

51 ses, dermatology, clinical pharmacology, and pharmacogenomics discussed the current state of drug all

52 t for therapies based on molecular genetics (pharmacogenomics, DNA microarrays, etc.) drives pharmace

53 RECENT FINDINGS: As the field of pharmacogenomics expands, more and more candidate genes

54 is of immediate use for prioritizing cancer pharmacogenomics experiments, and recovers known clinica

55 The rapidly expanding field of pharmacogenomics focuses on the genetic contributions to

56 In the case of pharmacogenomics, for instance, variants of consequence

57 understanding of cellular protein complexes, pharmacogenomics, genetic diagnosis and gene therapies.

58 Pharmacogenomics has employed candidate gene studies and

59 However, pharmacogenomics has made only a few inroads into clinic

60 The field of pharmacogenomics has seen some exciting advances in the

61 Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs

62 Pharmacogenomics holds great promise for the development

63 to leukemogenesis, drug resistance, and host pharmacogenomics, identified novel subtypes of leukemia,

64 Important associations of pharmacogenomics in cardiovascular medicine include clop

65 olizing enzymes, genetic susceptibility, and pharmacogenomics in determining cardiovascular disease r

66 review will discuss recent investigations of pharmacogenomics in heart failure, and the challenge of

67 udy was conducted to investigate the role of pharmacogenomics in NCPH in HIV patients with prior dida

68 the prospective study of population-related pharmacogenomics in which ethnic differences in antineop

69 d the first steps towards the integration of pharmacogenomics into clinical practice.

70 e polymorphism association studies in muscle pharmacogenomics is a field of expected future growth.

71 Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of dr

72 The impact of host pharmacogenomics is outlined.

73 The promise of pharmacogenomics is that it will one day result in targe

74 Pharmacogenomics is the study of how human genetic infor

75 Pharmacogenomics is the study of the inherited basis of

76 One of the goals of pharmacogenomics is the use of genetic variants to predi

77 Because one of the goals of pharmacogenomics is to identify individuals and target p

78 The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an i

79 The behavioural impact of pharmacogenomics is untested.

80 Through increased knowledge in the area of pharmacogenomics, it is hoped that that treatment of pai

81 named kinome-wide network module for cancer pharmacogenomics (KNMPx), for identifying actionable mut

82 rs, biomarkers, advanced cardiac imaging and pharmacogenomics may be used to classify patients at ris

83 spective study was performed by the Canadian Pharmacogenomics Network for Drug Safety using patients

84 n's Hospital, Memphis, TN) who discussed the pharmacogenomics of acute lymphoblastic leukemia as a ca

85 elet therapy in individuals (n=565) from the Pharmacogenomics of Anti-Platelet Intervention (PAPI) St

86 sease (epilepsy), genomics of drug response (pharmacogenomics of antiepileptic drugs) and genomics of

87 DESIGN, SETTING, AND PARTICIPANTS: In the Pharmacogenomics of Antiplatelet Intervention (PAPI) Stu

88 last year that address the pathogenesis and pharmacogenomics of asthma.

89 o model basic tumor biology and to study the pharmacogenomics of BCa.

90 gations of minimal residual disease and host pharmacogenomics, offer promising avenues of research.

91 expression), response to treatment, and host pharmacogenomics offers the potential to enhance or supp

92 icacy of ADT, establishing the importance of pharmacogenomics on individual's response to this therap

93 ern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large

94 ccurate local ancestry analysis in genetics, pharmacogenomics, population genetics, and clinical diag

95 ctronic Medical Records and Genomics Network Pharmacogenomics project from 7 US academic medical cent

96 omics, structural genomics, transcriptomics, pharmacogenomics, proteomics and metabolomics, allows fo

97 ere to assess the feasibility of prospective pharmacogenomics research in multicenter international c

98 The Pharmacogenomics Research Network and the Clinical Pharm

99 We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes ass

100 iew describes some of the recent advances in pharmacogenomics research.

101 rapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses

102 enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea th

103 The field of pharmacogenomics seeks to identify genetic factors that

104 ega-3 fatty acids), providing a means toward pharmacogenomics stratification of patients and monitori

105 This comprehensive pharmacogenomics study showed that individuals with the

106 Common and classic features of pharmacogenomics that are related to both antiretroviral

107 utine sample storage and processing has made pharmacogenomics the most widely applied discovery-based

108 colleagues took a different approach: using pharmacogenomics to focus on neural stem cell lineage, t

109 PMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding

110 Advances in the clinical application of pharmacogenomics to predict response to oncology therape

111 HIV and cancer medicine have used pharmacogenomics to some extent in clinical care.

112 genotyping may be required to define cancer pharmacogenomics unequivocally.

113 Pharmacogenomics will have an increasing role in the tre

114 rogress in the field of pharmacogenetics and pharmacogenomics will help further our understanding of

115 By resolving these hurdles, pharmacogenomics will yield significant, but incremental

116 germline genetics analysis methods to cancer pharmacogenomics with a focus on the special considerati

117 with a focus on monogenetic traits to become pharmacogenomics, with a genome-wide perspective.